Table 3.
Impact of the clinical-demographic, nutritional and genetic factors on the nutrition risk screening (NRS).
| Variable | NRS | |||
|---|---|---|---|---|
| <3 | ≥3 |
p OR [95%CI] |
||
| Gender | Male | 40 (67.80%) | 19 (32.20%) | 0.8901 |
| Female | 7 (70.00%) | 3 (30.00%) | 0.90 [0.21–3.88] | |
| Age (years) | ≥65 | 19 (65.52%) | 10 (34.48%) | 0.6935 |
| <65 | 28 (70.00%) | 12 (30.00%) | 0.81 [0.29–2.26] | |
| Histopathological diagnosis | Squamous-cell carcinoma | 45 (70.31%) | 19 (29.69%) | 0.1834 |
| Others | 2 (40.00%) | 3 (60.00%) | 3.55 [0.55–23.00] | |
| Tumor location | Oropharyngeal | 21 (72.41%) | 8 (27.59%) | 0.5150 |
| Others | 26 (65.00%) | 14 (35.00%) | 1.41 [0.50–4.01] | |
| Larynx | 23 (63.89%) | 13 (36.11%) | 0.4325 | |
| Others | 24 (72.73%) | 9 (27.27%) | 0.66 [0.24–1.84] | |
| T stage | T1–3 | 24 (66.67%) | 12 (33.33%) | 0.7874 |
| T4 | 23 (69.70%) | 10 (59.30%) | 0.87 [0.31–2.40] | |
| N stage | N0 | 13 (56.52%) | 10 (43.48%) | 0.1477 |
| N1–3 | 34 (33.26%) | 12 (66.74%) | 0.46 [0.16–1.32] | |
| M stage | M0 | 46 (67.65%) | 22 (32.35%) | 0.8216 |
| M1 | 1 (100.00%) | - | 0.69 [0.03–17.59] | |
| Disease stage | III | 12 (60.00%) | 8 (40.00%) | 0.3576 |
| IVA-IVC | 35 (71.43%) | 14 (28.57%) | 0.60 [0.20–1.78] | |
| Performance status (PS) | ≤1 | 39 (66.10%) | 20 (13.90%) | 0.3907 |
| >1 | 8 (80.00%) | 2 (20.00%) | 0.49 [0.09–2.51] | |
| Alcohol consumption | Yes | 19 (65.52%) | 10 (34.48%) | 0.6935 |
| No | 28 (70.00%) | 12 (30.00%) | 0.81 [0.29–2.26] | |
| Smoking status | Smoker | 35 (68.63%) | 16 (31.27%) | 0.8700 |
| Non-smoker | 12 (66.67%) | 6 (33.33%) | 1.09 [0.34–3.43] | |
| Concurrent C-RT | Yes | 17 (60.71%) | 11(39.29%) | 0.2779 |
| No | 30 (73.17%) | 11 (26.83%) | 0.57 [0.20–1.58] | |
| ITGAM genotype | AA | 20 (68.97%) | 9 (31.03%) | 0.8974 |
| GA or GG | 27 (67.50%) | 13 (32.50%) | 1.07 [0.38–2.99] | |
| GG | 4 (66.67%) | 2 (33.33%) | 0.9365 | |
| GA or AA | 43 (68.25%) | 20 (31.75%) | 0.93 [0.16–5.51] | |